Viridian Therapeutics, Inc.\DE VRDN Cash Flow Statement (2013-2026)

NASDAQ VRDN
$22.92 -0.04 (-0.17%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Viridian Therapeutics, Inc.\DE Quarterly Cash Flow Statement

Periods 52 quarters
Latest Jun 2026

Viridian Therapeutics, Inc.\DE reported cash from operations of -$105.32M and free cash flow of -$106.63M for the quarter ended Jun 2026, down 39.7% year over year. This cash flow statement covers 52 quarters of results from Jun 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-14.04M-28.95M-25.69M-29.49M-28.91M-45.78M-68.15M-55.06M-47.66M-66.67M-57.19M-72.96M-76.49M-79.47M-94.16M-100.73M-35.05M-118.24M-120.64M-126.08M
Share-based Compensation
3.98M3.49M4.66M4.88M4.94M5.28M15.22M12.30M13.61M26.05M12.69M11.77M8.72M8.97M10.22M10.84M11.25M11.99M13.39M16.98M
Cash from Discontinued Operations
Gains from Investment Securities
Asset Writedowns and Impairment
Cash from Operations
-11.88M-16.54M-21.04M-18.09M-20.67M-34.04M-61.97M-45.21M-38.98M-38.00M-45.22M-46.06M-67.71M-73.33M-92.65M-75.37M-84.61M-23.75M-119.65M-105.32M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-0.23M-0.25M-0.27M-0.26M-0.19M0.94M2.98M2.91M2.54M3.07M4.66M4.41M3.38M3.21M2.32M1.55M1.13M1.75M1.86M1.45M
Amortization of Deferred Charges
0.09M0.05M0.05M0.13M0.05M0.05M0.09M0.12M0.12M0.12M0.07M0.06M0.10M0.10M
Depreciation & Amortization (CF)Depreciation & Amortization
0.03M0.03M0.04M0.06M0.06M0.14M0.10M0.13M0.14M0.15M0.14M0.14M0.13M0.12M0.12M0.11M0.11M0.16M0.12M0.12M
Change in Working Capital
Change in Receivables
Change in Inventory
Change in Account Payables
1.46M-1.41M0.03M1.70M8.05M1.75M-6.65M-3.77M-0.11M-1.52M0.48M0.44M2.93M-3.92M1.76M4.63M1.55M-1.38M4.63M-5.20M
Change in Accured Expenses
-5.93M1.63M0.48M5.48M-4.25M6.00M2.58M2.64M-5.03M4.53M-0.89M7.53M3.91M10.79M-15.90M6.18M4.61M21.32M-23.69M6.11M
Other Working Capital Changes
0.12M-0.78M0.74M0.78M1.10M0.72M2.09M3.52M-1.13M-2.38M4.47M-3.13M3.91M6.41M-0.28M-5.19M-3.37M8.59M2.33M2.40M
Investing Activities
Capital Expenditures
0.13M0.08M0.18M0.29M0.10M0.23M0.28M0.16M0.40M0.05M0.10M0.29M0.11M0.09M0.04M0.13M0.24M0.02M1.31M
Sales of Property, Plant and Equipment
0.00M0.00M
Acquisitions
Change in Acquisitions & Divestments
24.60M22.76M14.23M14.26M42.75M37.70M64.10M49.10M98.49M102.83M82.56M121.34M144.05M118.98M171.39M131.51M140.29M99.01M168.60M148.80M
Cash from Investing Activities
6.25M-80.21M8.86M13.96M42.65M-180.60M-13.29M40.71M48.04M-169.71M-143.04M61.98M-84.67M-62.91M100.06M75.72M126.08M-339.42M77.26M-231.16M
Financing Activities
Other financing activities
0.94M0.35M0.67M0.00M0.26M1.83M6.94M2.13M0.71M100.03M0.84M0.21M382.70M2.30M0.76M0.55M285.44M6.36M137.39M
Debt Issuance and Repayment
Long-Term Debt Issuances
-0.45M0.45M
Change in Capital Stock
Net Shares Issued and Repurchased
Net Equity Issued and Repurchased
32.40M32.40M266.79M24.20M76.19M186.26M-150.00M33.65M4.94M0.00M9.80M48.24M
Dividend Payments
Dividends Paid - Common
Misc.
Cash from Financing Activities
116.79M0.17M0.74M4.56M290.93M26.01M8.20M3.07M15.46M198.94M177.08M0.11M245.02M35.52M9.21M0.76M10.86M405.91M6.36M325.12M
Change in Cash
111.17M-96.58M-11.44M0.43M312.92M-188.63M-67.06M-1.43M24.52M-8.77M-11.19M16.03M92.65M-100.72M16.62M1.11M52.32M42.73M-36.04M-11.36M
Free Cash Flow
-12.01M-16.62M-21.22M-18.38M-20.76M-34.27M-62.26M-45.38M-39.39M-38.05M-45.22M-46.16M-68.00M-73.45M-92.74M-75.42M-84.74M-23.99M-119.68M-106.63M
Net Cash Flow
111.17M-96.58M-11.44M0.43M312.92M-188.63M-67.06M-1.43M24.52M-8.77M-11.19M16.03M92.65M-100.72M16.62M1.11M52.32M42.73M-36.04M-11.36M